Sign in
APGE Stock Price, Chart, Stats & News
Apogee Therapeutics, Inc.
Save
8.21B
Market cap
–
Current P/E
–
Forward P/E
APGE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.11% |
ROA | -27.30% |
ROE | -36.77% |
D/E | 0.01x |
Interest coverage ratio | – |
APGE valuation
P/E | – |
P/S | – |
P/B | 5.23x |
P/CF | -20.76x |
P/FCF | -18.74x |
P/OCF | -20.76x |
PEG | -4.28x |
EV multiple | -16.12x |
About
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD.
Similar securities
Based on sector and market capitalization
Report issue